• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 28th November 2018

Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe

Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session. We have just published a new OHE Briefing entitled ‘Multi-Indication Pricing: Practical Solutions and Steps to Move Forward’, which summarises the discussion of a…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.

We have just published a new OHE Briefing entitled ‘Multi-Indication Pricing: Practical Solutions and Steps to Move Forward’, which summarises the discussion of a panel session held at the HTAi 2017 meeting in Rome.

Multi-indication pricing (MIP) is based on the concept of rewarding the value of individual indications (or patient sub-groups) for which a product is authorised. MIP can increase both static and dynamic efficiency: prices will be set at a cost-effective level, thus opening treatment access to more patients, and will stimulate future research, because manufacturers can recoup R&D costs more easily.

Despite the theoretical attractiveness of MIP, health care system stakeholders perceive that the implementation of MIP is associated with a number of challenges. Previous work by the OHE, in Europe, and the Institute for Clinical and Economic Review (ICER), in the US, has identified concerns with respect to inadequate data capabilities to monitor the prescription of different indications, legal and regulatory hurdles, and inflexibility of formulary structure to accommodate multi-indications.

The speakers of this HTAi panel session discussed the approaches used to handle the price of medicines with multiple indications in Europe, while also sharing the most important challenges and success stories of MIP from the perspectives of the payers and the industry.

In Europe, multi-indication products are priced using: the price of the first indication reimbursed across all indications (Netherlands, Norway and Poland), a single price ‘weighted’ by the value of each indication (Germany, France, Belgium and Austria) or individual prices for each indication (Italy). De facto, only the second and the third approaches are designed to reflect the value of the product indications portfolio. In the UK, even though indications are reviewed individually and only those deemed cost-effective are recommended, the price of new medicines does not change when additional indications are introduced, because only one Patient Access Scheme is usually allowed per product.

From the payers’ perspective, MIP may pose the risk of a higher budget impact if more patients gain access to treatment. In fact, MIP allows the industry to appropriate the consumer surplus during the patent period. In countries with an explicit cost-effectiveness threshold (e.g. the UK) companies may have an incentive to price at the maximum level allowed by the threshold. Therefore, payers also want to ensure that they can demand discounts based on budget impact and affordability.

However, implementing MIP over an optimal patent period can foster R&D and the development of in-class competition, which in turn has a lowering effect on the level of prices.

Payers are also concerned about the complexity of MIP and the resources (e.g. staff from the department of health) required to implement it. Despite the payers’ preference for simpler approaches, outcomes, and not only patient numbers, should be tracked in order to address the uncertainty attached to the product value. The online registries set up in Italy to collect data on patient eligibility and outcomes, and to support the implementation of outcome-based agreements, represent a successful MIP story.

From an industry perspective, without MIP there is an incentive to focus on small/high-value indications rather than expanding the use of existing molecules into further indications (within and outside the therapy area). Practically, the key challenge is the lack of data capabilities (in most systems) that can monitor different uses of the same medicine.

Steps to move forward with the adoption of MIP should aim at joining responsibility and goals of payers and industry. The role of stakeholders’ engagement will be a key factor in advancing this process.

For more information on this report please contact Margherita Neri.

Citation

Neri, M., Towse, A. and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward. OHE Briefing. London: Office of Health Economics. RePEc

Related research

Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M., 2015. Multi-indication pricing: pros, cons and applicability to the UK. OHE Seminar Briefing. London: Office of Health Economics. RePEc.

Pearson, S.D., Dreitlein, W.B., Henshall, C. and Towse, A., 2017. Indication-specific pricing of pharmaceuticals in the US healthcare system. Journal of Comparative Effectiveness Research, 6(5), pp.397–404. DOI.

Cole, A. & Towse, A. & Lorgelly, P. & Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper. London: Office of Health Economics. RePEc.

Towse, A., Cole, A. and Zamora, B., 2018. The Debate on Indication-Based Pricing in the US and Five Major European Countries. OHE Consulting Report. London: Office of Health Economics. RePEc.

  • Drug Development/R&D
  • Economics of Innovation
  • Briefing

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!